MUCOSAL DRUG DELIVERY

WELCOME

20|20 OptimEyes Technologies is a biotechnology spin-out company from McMaster University located in Hamilton, Ontario, Canada. We are developing a transformative drug for mucosal delivery while initially focusing on eye drops. Using a patented technology formulation, initially targeted for glaucoma and dry eye diseases, we are able to change the dosing paradigm from twice daily to once or twice weekly. This will revolutionize treatment for patients, improving their comfort, compliance and clinical outcomes.

OptimEyes’ MNP technology is a next generation drug delivery platform that maximizes the efficacy of new and existing APIs to improve patients lives